Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
UCLA Clinical Genomics Center, |
RCV000197751 | SCV000255374 | likely pathogenic | Deafness-lymphedema-leukemia syndrome; Monocytopenia with susceptibility to infections | 2013-07-16 | criteria provided, single submitter | clinical testing | |
Molecular Pathology Research Laboratory, |
RCV001542124 | SCV001760792 | pathogenic | Deafness-lymphedema-leukemia syndrome; GATA2 deficiency with susceptibility to MDS/AML | 2021-07-06 | criteria provided, single submitter | curation | PS1, PS4, PM1, PM2, PP3 |
Labcorp Genetics |
RCV000197751 | SCV003525660 | pathogenic | Deafness-lymphedema-leukemia syndrome; Monocytopenia with susceptibility to infections | 2023-06-03 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GATA2 protein function. ClinVar contains an entry for this variant (Variation ID: 216931). This missense change has been observed in individual(s) with GATA2-related conditions and/or myelodysplastic syndrome (PMID: 21670465, 24077845, 26702063; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces asparagine, which is neutral and polar, with lysine, which is basic and polar, at codon 371 of the GATA2 protein (p.Asn371Lys). |